Clinical Trial Update: Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus [NA]

View source ↗

Summary

This document indicates that a clinical trial evaluating Physiologic Insulin Resensitization (PIR) in patients with chronic kidney disease and diabetes mellitus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Physiologic Insulin Resensitization (Physiologic Insulin Resensitization)

Snippet

Sponsor: Well Cell Global | Conditions: Chronic Kidney Disease (Stages 4 and 5), Kidney Disease | NA | Status: RECRUITING